Current Clinical Trials
Every day, thousands of people—HIV positive and negative—volunteer to participate in HIV-related, clinical research trials. Because of these brave women and men, modern medicine continues to discover new and more powerful HIV treatments and prevention strategies.
Today, AIDS Research Alliance conducts an array of HIV/AIDS clinical trials, and we need many more research volunteers. Currently, we seek diverse volunteers (all ages, genders, ethnicities, and sexual orientations and HIV status) for 4 clinical research studies.
If you are interested in any of these studies, please call Leo at (310) 358-2429 or email studyinfo@aidsresearch.org
Currently Enrolling Studies:
HIV Vaccine Study new
Do You Experience HIV-Associated Diarrhea?: Anti-Diarrhea Treatment Study
Elite Controller:A Study for HIV-Positive Persons Who are Not on Meds
Ongoing Studies, closed to new enrollment:
POM Wonderful 08/2006 to present
Protocol POM ARA011: A Phase I/II, Proof-of-Concept, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effects of Punica Granatum (Pomegranate) Juice on the Indices of Quality of Life in HIV Positive Patients
The
National Institute of Neurological Disorders and Stroke (NINDS), The Neurologic
AIDS Research Consortium (NARC), & Novartis 03/2009 to present
Protocol
NARC011: A Phase II, Randomized, Double-Blind, Placedbo –Controlled Study of Methadone and Combination of Methadone and SAB378 in
HIV-Associated Painful Peripheral Neuropathy
Merck
& Co., Inc., & Division of AIDS, NIH 12/08 to present
Protocol
HVTN 504: Observational follow-up of adult participants
enrolled in the Step Study (Merck V520 Protocol 023/HVTN 502), a
3-dose regimen of the Merck MRK Ad5 HIV-1 gag/pol/nef vaccine or placebo
CHRP 09/07 to
present
California
HIV/ AIDS Research Program, ARA012: Women’s Attitudes towards Microbicides and Clinical Trials
Theratechnologies, Inc. 09/07 to present
Protocol
TH9507-CTR-1012: A Multicenter, Double-Blind, Randomized, Placebo-Controlled
Extension Study Assessing the Efficacy and Long-Term Safety of a 2 MG Dose of
TH9507, A Growth Hormone Releasing Factor Analog, in HIV Subjects with Excess
Abdominal Fat Accumulation
Numico Research, B.V. 01/07 to
present
Protocol
100157, BITE study: A Randomised, Double-blind,
Controlled Study on the Effect of One Year Administration of a Nutritional
Concept on Immunological Status in HIV-1 Positive Adults not on Antiretroviral
Therapy
Merck
& Co., Inc. 1/05 to present
Double-blind,
Randomized, Dose-Ranging Placebo-Controlled Study to Evaluate the Safety,
Pharmacokinetics and Antiretroviral Activity of L-000900612 in Combination With
an Optimized Background Therapy (OBT), Versus Optimized Background Therapy
Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug
in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies
Merck
& Co., Inc. 11/04 to present
A
Multicenter Double-blind, Randomized, Placebo-controlled Phase II Proof of
Concept Study to Evaluate the Safety, and Efficacy of a 3 Dose Regimen of the
Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) in a Prime-Boost
Regimen in Adults at High Risk of Infection
Merck
& Co., Inc. 7/03 to present
Protocol
016: A Phase I Dose-Ranging Study of the Safety, Tolerability, and
Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef)
in a Prime-Boost Regimen in Healthy Adults
Volunteer for an HIV vaccine study and turn hope into action. Don’t worry. You can’t get HIV from the vaccine.
Eligible volunteers will receive $50 for each study visit after enrollment.
Call Leo at 310.358.2429 or email studyinfo@aidsresearch.org for more information.
Do You Experience HIV-Associated Diarrhea?:
Anti-Diarrhea Treatment Study
AIDS Research Alliance is studying an investigational drug called crofelemer for the treatment of HIV-associated diarrhea.
Crofelemer comes from a tree found in South America that has been widely used for its medicinal properties, including the treatment of diarrhea.
You may be eligible if you: 
- Are at least 18-years old
- Are HIV-positive and on HIV meds
- Had diarrhea for at least one month
Study Volunteers will:
- Part 1: Receive either the research drug (crofelemer) or a placebo (an inactive drug).
- Part 2: All receive the research drug.
Study Volunteers will be compensated between $75 and $100 per study visit for their time and inconvenience.
If you are interested in this study, please call Leo at (310) 358-2429 or email studyinfo@aidsresearch.org
Return to top
Elite Controller:
A Study for HIV-Positive Persons Who are Not on Meds
AIDS Research Alliance is studying persons living with HIV who are long-term non-progressors.
You may be eligible if you are:
- At least 18-years old
- HIV-positive with a viral load less than 2,000 for 12 months
- Not taking HIV meds
Study Volunteers will:
- Visit the clinic for a brief medical history and a single blood draw.
Study Volunteers will be compensated $25 for their time and inconvenience.
If you are interested in any of these studies, please call Leo at (310) 358-2429 or email studyinfo@aidsresearch.org
Return to top
The world’s leading pharmaceutical and bio-tech companies rely on the expertise of AIDS Research to conduct innovative, meaningful and cost-efficient clinical trials. These trials are overseen by ARA’s own Institutional Review Board, who review and approve the trial to protect the civil rights of research volunteers and ensure their safety.
Click here to find out how to become involved with clinical trials.
You can also enroll in our Trials Alert List to stay informed of new studies at ARA when they become available. Trials Alert List Sign-up Form
